eduKateSG · Why Science?
Separate an expedited development programme from the decision to market
Use FDA Breakthrough Devices resources through eligibility criteria, designation requests, interactive review, PMA, De Novo and 510(k) pathways, public lists, decision summaries, withdrawal and evidence limits.
The Breakthrough Devices Program is meant to help eligible medical devices for serious conditions move through development, assessment and review with more timely interaction. That makes it a fascinating example of regulation trying to support innovation without discarding evidence standards.
The key reading habit is simple: keep designation and marketing authorization in separate columns. One opens a programme route; the other is the later FDA decision under PMA, De Novo or 510(k).
Did you know? A device can receive Breakthrough Device designation before its human clinical programme is complete. It still must meet the applicable standard before FDA authorizes marketing.
This guide supports science and regulatory literacy. It does not endorse a device or predict a regulatory outcome.
Chapter index
Chapters 1–9: designation criteria, interaction and development
- 1. The programme addresses serious conditions
- 2. A second eligibility route is also required
- 3. Designation can occur before clinical evidence is complete
- 4. Designation is not marketing authorization
- 5. The eventual pathway still matters
- 6. Interactive communication is a programme feature
- 7. Clinical-study design can be discussed early
- 8. Manufacturing and quality remain part of review
- 9. Priority attention does not mean automatic speed
Chapters 10–17: marketing pathway, public status and decision evidence
- 10. Benefit-risk remains pathway-specific
- 11. Public designation information has limits
- 12. Authorised-device lists need exact status
- 13. Decision summaries carry the evidence
- 14. Designation can be withdrawn
- 15. Breakthrough Device differs from Breakthrough Therapy
- 16. Coverage and payment are separate questions
- 17. A complete evidence receipt follows both stages
Breakthrough Device designation becomes meaningful when eligibility, designation date, regulatory pathway and later marketing decision stay separate. A device must provide for more effective treatment or diagnosis of a life-threatening or irreversibly debilitating disease or condition to meet the first statutory criterion. This preserves the difference between a development programme and a marketing authorization.
Try this
Evidence question: Which official record or guidance supports the point about the programme addresses serious conditions? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for the programme addresses serious conditions. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for the programme addresses serious conditions, its identifier or version context, and one limit that must remain visible.
The programme is designed to expedite interaction and review for eligible devices addressing serious conditions. The device must represent breakthrough technology, have no approved or cleared alternatives, offer significant advantages over existing alternatives, or have availability in patients’ best interest. It also avoids confusing Breakthrough Devices with the drug Breakthrough Therapy pathway.
Try this
Evidence question: Which official record or guidance supports the point about a second eligibility route is also required? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for a second eligibility route is also required. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for a second eligibility route is also required, its identifier or version context, and one limit that must remain visible.
CHAPTER 3 OF 17 · Test eligibility
3. Designation can occur before clinical evidence is complete
Designation does not itself authorize sale, prove clinical benefit or guarantee a favourable marketing decision. A sponsor may request designation before the marketing submission, including while development and evidence plans are still evolving. Designation and decision records make the route auditable.
Try this
Evidence question: Which official record or guidance supports the point about designation can occur before clinical evidence is complete? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for designation can occur before clinical evidence is complete. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for designation can occur before clinical evidence is complete, its identifier or version context, and one limit that must remain visible.
Public counts and authorised-device lists need dates because the programme continues to change. A designated device cannot be marketed solely because FDA granted Breakthrough Device designation. Evidence standards still apply through PMA, De Novo or 510(k).
Try this
Evidence question: Which official record or guidance supports the point about designation is not marketing authorization? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for designation is not marketing authorization. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for designation is not marketing authorization, its identifier or version context, and one limit that must remain visible.
Breakthrough Device designation becomes meaningful when eligibility, designation date, regulatory pathway and later marketing decision stay separate. The programme can support devices later reviewed through PMA, De Novo or 510(k), and each pathway retains its applicable statutory standard. This preserves the difference between a development programme and a marketing authorization.
Try this
Evidence question: Which official record or guidance supports the point about the eventual pathway still matters? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for the eventual pathway still matters. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for the eventual pathway still matters, its identifier or version context, and one limit that must remain visible.
CHAPTER 6 OF 17 · Read programme features
6. Interactive communication is a programme feature
The programme is designed to expedite interaction and review for eligible devices addressing serious conditions. FDA and sponsors can use timely interaction to identify efficient and flexible approaches to evidence development and review. It also avoids confusing Breakthrough Devices with the drug Breakthrough Therapy pathway.
Try this
Evidence question: Which official record or guidance supports the point about interactive communication is a programme feature? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for interactive communication is a programme feature. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for interactive communication is a programme feature, its identifier or version context, and one limit that must remain visible.
CHAPTER 7 OF 17 · Read programme features
7. Clinical-study design can be discussed early
Designation does not itself authorize sale, prove clinical benefit or guarantee a favourable marketing decision. Programme interaction may address endpoints, populations, evidence needs and efficient study approaches without predetermining the final decision. Designation and decision records make the route auditable.
Try this
Evidence question: Which official record or guidance supports the point about clinical-study design can be discussed early? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for clinical-study design can be discussed early. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for clinical-study design can be discussed early, its identifier or version context, and one limit that must remain visible.
CHAPTER 8 OF 17 · Read programme features
8. Manufacturing and quality remain part of review
Public counts and authorised-device lists need dates because the programme continues to change. Expedited interaction does not remove design-control, manufacturing, software, biocompatibility or other applicable evidence responsibilities. Evidence standards still apply through PMA, De Novo or 510(k).
Try this
Evidence question: Which official record or guidance supports the point about manufacturing and quality remain part of review? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for manufacturing and quality remain part of review. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for manufacturing and quality remain part of review, its identifier or version context, and one limit that must remain visible.
CHAPTER 9 OF 17 · Follow the pathway
9. Priority attention does not mean automatic speed
Breakthrough Device designation becomes meaningful when eligibility, designation date, regulatory pathway and later marketing decision stay separate. Review timing depends on the device, evidence, submission quality, questions and available resources; designation does not promise a fixed authorization date. This preserves the difference between a development programme and a marketing authorization.
Try this
Evidence question: Which official record or guidance supports the point about priority attention does not mean automatic speed? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for priority attention does not mean automatic speed. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for priority attention does not mean automatic speed, its identifier or version context, and one limit that must remain visible.
The programme is designed to expedite interaction and review for eligible devices addressing serious conditions. FDA still evaluates whether the submitted evidence meets the standard for approval, clearance or De Novo classification. It also avoids confusing Breakthrough Devices with the drug Breakthrough Therapy pathway.
Try this
Evidence question: Which official record or guidance supports the point about benefit-risk remains pathway-specific? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for benefit-risk remains pathway-specific. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for benefit-risk remains pathway-specific, its identifier or version context, and one limit that must remain visible.
Designation does not itself authorize sale, prove clinical benefit or guarantee a favourable marketing decision. FDA publishes programme information and selected device details, but not every confidential development fact is public before authorization. Designation and decision records make the route auditable.
Try this
Evidence question: Which official record or guidance supports the point about public designation information has limits? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for public designation information has limits. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for public designation information has limits, its identifier or version context, and one limit that must remain visible.
Public counts and authorised-device lists need dates because the programme continues to change. A public list of Breakthrough Devices that received marketing authorization concerns a subset of designated devices and should not be used as the designation total. Evidence standards still apply through PMA, De Novo or 510(k).
Try this
Evidence question: Which official record or guidance supports the point about authorised-device lists need exact status? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for authorised-device lists need exact status. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for authorised-device lists need exact status, its identifier or version context, and one limit that must remain visible.
CHAPTER 13 OF 17 · Verify the final decision
13. Decision summaries carry the evidence
Breakthrough Device designation becomes meaningful when eligibility, designation date, regulatory pathway and later marketing decision stay separate. After marketing authorization, the PMA summary, De Novo decision summary or 510(k) summary explains the actual basis for the regulatory outcome. This preserves the difference between a development programme and a marketing authorization.
Try this
Evidence question: Which official record or guidance supports the point about decision summaries carry the evidence? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for decision summaries carry the evidence. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for decision summaries carry the evidence, its identifier or version context, and one limit that must remain visible.
The programme is designed to expedite interaction and review for eligible devices addressing serious conditions. FDA guidance describes circumstances and procedures for withdrawal, so a historic designation statement should be checked against current status. It also avoids confusing Breakthrough Devices with the drug Breakthrough Therapy pathway.
Try this
Evidence question: Which official record or guidance supports the point about designation can be withdrawn? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for designation can be withdrawn. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. If a field is missing, write “not shown” and follow the official documentation rather than inventing a value.
Evidence checkpoint
Record the evidence object for designation can be withdrawn, its identifier or version context, and one limit that must remain visible.
CHAPTER 15 OF 17 · Verify the final decision
15. Breakthrough Device differs from Breakthrough Therapy
Designation does not itself authorize sale, prove clinical benefit or guarantee a favourable marketing decision. The device programme and the drug and biologic Breakthrough Therapy designation arise under different provisions and should never be merged. Designation and decision records make the route auditable.
Try this
Evidence question: Which official record or guidance supports the point about breakthrough device differs from breakthrough therapy? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for breakthrough device differs from breakthrough therapy. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Before comparing two records, check that their object types, methods, versions and units really align.
Evidence checkpoint
Record the evidence object for breakthrough device differs from breakthrough therapy, its identifier or version context, and one limit that must remain visible.
CHAPTER 16 OF 17 · Verify the final decision
16. Coverage and payment are separate questions
Public counts and authorised-device lists need dates because the programme continues to change. FDA marketing authorization does not itself determine insurance coverage, coding, payment or health-system adoption. Evidence standards still apply through PMA, De Novo or 510(k).
Try this
Evidence question: Which official record or guidance supports the point about coverage and payment are separate questions? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for coverage and payment are separate questions. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Finish by naming one supported statement and one stronger statement that still needs another evidence layer.
Evidence checkpoint
Record the evidence object for coverage and payment are separate questions, its identifier or version context, and one limit that must remain visible.
CHAPTER 17 OF 17 · Verify the final decision
17. A complete evidence receipt follows both stages
Breakthrough Device designation becomes meaningful when eligibility, designation date, regulatory pathway and later marketing decision stay separate. Record the designation claim, criteria, date and source, then separately record the later pathway, decision number, date, summary and current labeling. This preserves the difference between a development programme and a marketing authorization.
Try this
Evidence question: Which official record or guidance supports the point about a complete evidence receipt follows both stages? Answer in three parts: identify the visible field or file, explain how it bears on the question, and state the boundary of that evidence. Preserve the database’s own object names and accession rather than flattening everything into the word ‘data’.
Try this: Save the identifier, date, source and one limit for a complete evidence receipt follows both stages. Turn the result into a compact claim-evidence-reasoning note, then ask a partner to retrace it. Keep the identifier, retrieval date and source page in the note so the route can be repeated.
Evidence checkpoint
Record the evidence object for a complete evidence receipt follows both stages, its identifier or version context, and one limit that must remain visible.
Contents · Previous chapter · Continue at the Science Learning Hub
A breakthrough claim is trustworthy when designation and marketing evidence remain distinct
The programme creates a faster conversation around eligible technologies. Scientific confidence comes from following that conversation into the actual submission, decision summary and current labeling.
Save the device and sponsor, serious condition, eligibility basis, designation date and source, development stage, regulatory pathway, marketing submission number, decision date, decision summary, labeling, current status and access date.
| Reading object | What it can support | Question to keep visible |
|---|---|---|
| Designation | Entry to the Breakthrough Devices Program | Which criteria were met? |
| Programme interaction | FDA and sponsor communication during development | What question was addressed? |
| Marketing submission | PMA, De Novo or 510(k) evidence package | Which standard applies? |
| Authorization | FDA decision permitting marketing | Which decision summary supports it? |
Sources and next reading
Substantive resource claims in this article were checked against the primary pages below. A structured record is a route into evidence; it does not by itself prove a scientific conclusion. Recheck the live record, evidence labels and release context before using it in assessed work or research.
For a classroom enquiry, save a short research receipt containing the question, search terms, selected object, exact identifier, version, access date and the evidence boundary you observed. Add the file or page that supports each statement. This small routine turns browsing into accountable science learning and gives a teacher, classmate or future analyst a route they can independently follow.
Before sharing the conclusion, ask another reader to retrace the route without verbal hints. If they reach a different version, file or interpretation, improve the receipt and narrow the claim. Reproducibility begins with this practical check. It teaches careful reading, supports fair collaboration and keeps uncertainty visible while evidence moves from an online service into notes, analysis and a final explanation.
A useful final review separates five questions. What object was found? Which organisation or repository maintains it? What exact evidence was inspected? Which statement does that evidence support? What remains uncertain? Answer each question in one sentence, then connect every answer to a visible field, file or source page. This review catches common mistakes: citing a collection when a file supplied the value, treating the newest release as the analysed release, confusing permission with scientific suitability, or turning a discovery count into a conclusion. It also gives students a calm way to improve work. A missing detail becomes a next research step instead of an invitation to guess. When the route is complete, the final explanation can stay simple because the identifiers, dates, versions, limitations and supporting evidence are already organised underneath it.
Primary sources
- FDA Breakthrough Devices Program — accessed 25 October 2026.
- FDA Breakthrough Devices Final Guidance — accessed 25 October 2026.
- FDA How to Study and Market Your Device — accessed 25 October 2026.
- FDA PMA Database — accessed 25 October 2026.
- FDA De Novo Database — accessed 25 October 2026.